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cancer needs to be evaluated against the alternative of adjuvant
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Sir,
The results of the trial of Klautke et al (2006). ‘Concurrent
chemoradiation with capecitabine and weekly irinotecan as
preoperative treatment for rectal cancer: results from a phase I/II
study’ create concerns regarding the toxicity of their scheme.
Although they report good results in terms of local disease
control, their mortality of two out of 28 patients or 7.1% is
worryingly high.
Similar concerns are raised by another recent study on neo-
adjuvant radio-chemotherapy on rectal cancer, by Chau et al
(2006). ‘Neo-adjuvant capecitabine and oxaliplatin followed by
synchronous chemoradiation and total mesorectal excision in
magnetic resonance imaging-defined poor-risk rectal cancer’. In
that study four out of 77 patients or 5.1% died during the neo-
adjuvant treatment.
Although neo-adjuvant treatment has often impressive
temporary results in local response it should be kept in mind
that the so far proven survival benefit is small and around or below
10%. If this has to be counterbalanced with a 5–7% mortality risk
from neo-adjuvant treatment plus 3–5% risk of major rectal
surgery, then we may end up with the combined risks of the two
modalities outweighing the long-term improvement of survival
probability.
Adjuvant chemo-radiotherapy carries similar toxicity but it
allows more accurate selection of those patients who have
pathological, rather than radiological, staging plus other patholo-
gical risk factors such as infiltrated margins, perineural or
lymphovascular invasion. The risk of toxicity on those patients
of proven high risk would be more acceptable to both clinician and
patient.
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